Published in J Am Coll Cardiol on February 01, 1998
Dynamic morphology of the secundum atrial septal defect evaluated by three dimensional transoesophageal echocardiography. Heart (2000) 0.96
Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography. Clin Res Cardiol (2010) 0.81
Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis. Int J Cardiovasc Imaging (2015) 0.78
DDDR pacing for symptomatic patients with hypertrophic obstructive cardiomyopathy: The first experience in the Netherlands with pacing in HOCM. Neth Heart J (2002) 0.75
Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol (1998) 0.75
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation (1994) 3.41
Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation (1992) 2.67
Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest (1993) 2.04
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1993) 1.89
Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest (1995) 1.75
Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A (1995) 1.70
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br Med J (Clin Res Ed) (1984) 1.69
Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation (2001) 1.63
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation (1992) 1.63
Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation (2000) 1.58
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet (2002) 1.56
R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil (2000) 1.44
Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol (2000) 1.44
The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil (1997) 1.40
Excess smoking in malignant-phase hypertension. Br Med J (1979) 1.38
Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 1.35
Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation (1995) 1.34
Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy. Circulation (1992) 1.29
Neurological dysfunction in two patients receiving captopril and cimetidine. Lancet (1980) 1.20
Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6). J Med Genet (2004) 1.16
Structural and functional responses of mammalian thick filaments to alterations in myosin regulatory light chains. J Struct Biol (1998) 1.12
Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation (2001) 1.09
Reliability of the evoked response in determining the paced ventricular rate and performance of the QT or rate responsive (TX) pacemaker. Pacing Clin Electrophysiol (1985) 1.09
Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation (1991) 1.06
Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol (1990) 1.05
Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid). Br Heart J (1980) 1.01
Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 0.97
Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. Am J Cardiol (1994) 0.93
The possible relation between late pregnancy hypertension and 5-hydroxytryptamine levels in maternal blood. Br J Obstet Gynaecol (1979) 0.92
Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol (2001) 0.91
Atrial synchronized ventricular pacing: contribution of the chronotropic response to improved exercise performance. Pacing Clin Electrophysiol (1983) 0.90
Ventricular septal defect after myocardial infarction: assessment by cross sectional echocardiography with pulsed wave Doppler scanning. Br Heart J (1987) 0.88
Inverse relation of exchangeable sodium and blood pressure in hypertensive patients with renal artery stenosis. J Hypertens (1983) 0.87
Comparison of resting hemodynamic indices and exercise performance during atrial synchronized and asynchronous ventricular pacing. Pacing Clin Electrophysiol (1983) 0.86
Sudden cardiac death in hypertrophic cardiomyopathy. Circulation (1992) 0.85
Echocardiographic detection of perforation of the cardiac ventricular septum by a permanent pacemaker lead. Am J Cardiol (1987) 0.85
Right ventricular dysfunction and surgical outcome in postinfarction ventricular septal defect. Eur Heart J (1983) 0.85
Genetic evidence of dissociation (generational skips) of electrical from morphologic forms of hypertrophic cardiomyopathy. Am J Cardiol (1990) 0.85
Exchangeable sodium in DOC-salt and post-DOC-salt hypertension in rats. J Hypertens (1985) 0.84
Percutaneous balloon dilatation of the mitral valve in patients who were unsuitable for surgical treatment. Br Heart J (1992) 0.83
Regression of multiple pulmonary varices after mitral valve replacement. J Thorac Cardiovasc Surg (1980) 0.82
Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol (1997) 0.82
The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man. Clin Sci (Lond) (1981) 0.81
The renin-angiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestagen oral contraceptives. Clin Endocrinol (Oxf) (1983) 0.81
Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2000) 0.81
Minimum steriod requirements in renal transplant patients monitored by urinary fibrin degradation products and complement. Proc Eur Dial Transplant Assoc (1977) 0.81
A Fourier based algorithm for tracking SPAMM tags in gated magnetic resonance cardiac images. Med Phys (1996) 0.79
Exchangeable sodium in Goldblatt one-kidney one-clip hypertension in the rat. Clin Sci (Lond) (1984) 0.78
Effect of intravenous magnesium sulfate on blood magnesium parameters. Magnes Trace Elem (1990) 0.78
Hypertrophic obstructive cardiomyopathy: problems of management. Chest (1997) 0.77
Contribution of heart rate to QT interval shortening during exercise. Eur Heart J (1983) 0.77
Myocardial bridging in children with hypertrophic cardiomyopathy. N Engl J Med (1999) 0.77
Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation (1992) 0.77
Results of valve replacement with the Omniscience prosthesis. J Thorac Cardiovasc Surg (1983) 0.76
Heart rate variability and cardiac arrhythmias in patients with chronic renal failure. Clin Auton Res (1991) 0.76
Similarity of idiopathic aldosteronism and essential hypertension. A statistical comparison. Hypertension (1983) 0.76
VT and sudden death in HCM patients. Circulation (1989) 0.75
Staphylococcal septicaemia complicated by probable cloxacillin neurotoxicity and by jaundice induced by fusidic acid. Scott Med J (1983) 0.75
Wolff-Parkinson-White syndrome and sudden cardiac death. Cardiology (1987) 0.75
Comparison of single and divided daily dose spironolactone in the control of hypertension. Br J Clin Pharmacol (1981) 0.75
Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study. Br J Clin Pharmacol (1985) 0.75
Identification of patients with hypertrophic cardiomyopathy at high risk for sudden death. Curr Opin Cardiol (1995) 0.75
The 'third drug' trial: a comparative study of anti-hypertensive agents added to treatment when blood pressure is uncontrolled by a beta-blocker plus thiazide diuretic. J Hypertens Suppl (1983) 0.75
Advances in understanding hypertrophic cardiomyopathy. Hosp Pract (1995) (2001) 0.75
Computed tomography in the localization of aldosterone-secreting adrenal adenomas. Br J Radiol (1981) 0.75
Methods for testing autonomic control of heart rate. Table-tilt and metronomic breathing manipulations. J Electrocardiol (1993) 0.75
The effect of chronic prazosin therapy on the response of the renin-angiotensin system in patients with essential hypertension. J Hum Hypertens (1987) 0.75
Exchangeable sodium in rats with Goldblatt two-kidney one-clip hypertension. Clin Sci (Lond) (1982) 0.75
Suppression of incessant ventricular tachycardia in hypertrophic cardiomyopathy associated with improvement of severe left ventricular dysfunction. Pacing Clin Electrophysiol (1992) 0.75
Raised urinary fibrin-degradation products, complement, and IgG during an influenza-like illness. Lancet (1977) 0.75
Experience with 407 transvenous, finned pacing leads with a sintered porous-surfaced electrode. Pacing Clin Electrophysiol (1984) 0.75
Radiofrequency catheter atrioventricular node ablation in patients with permanent cardiac pacing systems. Pacing Clin Electrophysiol (1994) 0.75
Relief of left ventricular outflow tract obstruction following inadvertent left ventricular apical pacing in a patient with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol (1995) 0.75
Exchangeable sodium measured serially in DOC-salt, post-DOC-salt, and Goldblatt hypertension in the rat. J Cardiovasc Pharmacol (1984) 0.75
Long-term follow-up of patients with the QT rate adaptive pacemaker. Pacing Clin Electrophysiol (1989) 0.75
Urinary beta-thromboglobulin in essential hypertension. Br J Haematol (1980) 0.75
Body sodium and blood pressure: abnormal and different correlations in Conn's syndrome, renal artery stenosis and essential hypertension. Proc Eur Dial Transplant Assoc (1983) 0.75
Altered cardiac hemodynamic and electrical state in normal sinus rhythm after chronic dual-chamber pacing for relief of left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol (1992) 0.75
The measurement of exchangeable sodium and total body sodium in rats in vivo compared with chemical analysis postmortem. J Lab Clin Med (1983) 0.75
Comparison of vitreous carbon and elgiloy transvenous ventricular pacing leads. Pacing Clin Electrophysiol (1985) 0.75